Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer

[1]  R. Dienstmann,et al.  XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. , 2009, Urologic oncology.

[2]  G. Kristiansen,et al.  Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. , 2009, European urology.

[3]  G. Kristiansen,et al.  Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. , 2009, European journal of cancer.

[4]  G. Torzilli,et al.  Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma , 2009, BMC Cancer.

[5]  G. Kristiansen,et al.  Claudin-1 Protein Expression is a Prognostic Marker of Patient Survival in Renal Cell Carcinomas , 2008, Clinical Cancer Research.

[6]  Haiyang Xie,et al.  Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation , 2008, Annals of Surgical Oncology.

[7]  S. Takeno,et al.  Disturbed XIAP and XAF1 Expression Balance Is an Independent Prognostic Factor in Gastric Adenocarcinomas , 2008, Annals of Surgical Oncology.

[8]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[9]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[10]  G. Kristiansen,et al.  ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression , 2008, BMC Cancer.

[11]  K. Miller,et al.  Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome. , 2007, Cancer letters.

[12]  R. Korneluk,et al.  Degradation of Survivin by the X-linked Inhibitor of Apoptosis (XIAP)-XAF1 Complex* , 2007, Journal of Biological Chemistry.

[13]  M. Sata,et al.  X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues. , 2007, Oncology reports.

[14]  Kil Yeon Lee,et al.  Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. , 2007, Gastroenterology.

[15]  J. Gu,et al.  Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis , 2007, Cancer Gene Therapy.

[16]  J. Lam,et al.  Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Chi,et al.  Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses , 2006, Oncogene.

[18]  E. Borden,et al.  Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Duckett,et al.  Xaf1 can cooperate with TNFα in the induction of apoptosis, independently of interaction with XIAP , 2006, Molecular and Cellular Biochemistry.

[20]  M. Qiao,et al.  Low expression of XIAP-associated factor 1 in human colorectal cancers. , 2005, Chinese journal of digestive diseases.

[21]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[22]  M. Martinka,et al.  XAF1 expression is significantly reduced in human melanoma. , 2004, The Journal of investigative dermatology.

[23]  H E Gabbert,et al.  Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas , 2004, British Journal of Cancer.

[24]  T. Ebert,et al.  XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. , 2004, Human pathology.

[25]  D. Vaux,et al.  Cell death regulation by the mammalian IAP antagonist Diablo/Smac , 2002, Apoptosis.

[26]  John Calvin Reed,et al.  Endogenous Inhibitors of Caspases , 1999, Journal of Clinical Immunology.

[27]  Mamta Chawla-Sarkar,et al.  Novel Growth and Death Related Interferon-Stimulated Genes (ISGs) in Melanoma: Greater Potency of IFN-β Compared with IFN-α2 , 2003 .

[28]  Kyucheol Cho,et al.  Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. , 2003, Cancer research.

[29]  Mamta Chawla-Sarkar,et al.  Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[30]  E. Borden,et al.  Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[31]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[32]  K. Tamai,et al.  Identification of XAF1 as an antagonist of XIAP anti-Caspase activity , 2001, Nature Cell Biology.

[33]  R. Korneluk,et al.  Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. , 2000, Genomics.

[34]  L. Schwartz,et al.  Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[36]  J C Reed,et al.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[38]  John Calvin Reed.  Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. MacKenzie,et al.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.

[40]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[41]  R. Motzer,et al.  Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.